Status Topic selection
Technology type Medicine
Decision Not selected
Further information Decision makers have concluded that the clear rationale to not evaluate your product is due to a clinical guideline (CG150) being available that already which includes a recommendation for the use of combination therapy with an oral triptan and an NSAID for the acute treatment of migraine. Therefore, a TA would not add any further value.
ID number 12055

Project Team

Project lead Danielle Lees

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 September 2024 Topic selection

For further information on how we select topics for development, please see our page about prioritising our guidance topics